Drilldown: Medicines
Medicines > classes:
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] 
& duration :
12 hours or
24 hours
& duration :
12 hours or
24 hours Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (5) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
10 mg PO once daily in the morning; 5 mg starting in heart failure (1) ·
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
15-30 mg PO once daily; titrate to 45 mg (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1)
preparations:
fda max:
routes:
onset:
1-2 hours (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) ·
HbA1c effect at 12-16 weeks (slower than other classes) (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (2)
duration: (Click arrow to add another value)
halflife:
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) ·
~3-7 hours (parent); 16-24 hours including active metabolites'"`UNIQ--ref-00000824-QINU`"' (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1)
bioavailability:
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"' (1) ·
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 6 results in range #1 to #6.